Építés alatt – nem éles oldal
Belépés
Visszavonva3. fázis

Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

A legfontosabb adatok

Ki végzi
Apellis Pharmaceuticals, Inc.
Hol
Brazília1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Visszavonva
Fázis
3. fázis
Kezdés
2026. máj. 18.
Várható befejezés
2030. júl.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Pegcetacoplan
  • Placebo
A regiszteradat frissítve
2026. szeptember 2.
Miért állt le
The study was terminated following portfolio reprioritization and reallocation of resources to other development programs. The decision was not driven by safety or efficacy concerns arising from this trial.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Aged at least 18 years
  • Have end-stage kidney disease and be on the waiting list for a kidney transplant from a deceased donor
  • Be on dialysis at the time of your transplant and produce very little urine (less than 200 mL per day equivalent to ≤1 cup). You must have been on dialysis for at least 3 months
  • Be receiving your first or second kidney transplant from a deceased donor. If this is your second transplant:; It cannot be due to a serious infection or a serious blood clot in your previous transplant; Your calculated Panel Reactive Antibody (CPRA) level must be below 50%
  • Be getting a donor kidney that meets the study's specific requirements
  • Be at low to medium risk of transplant rejection, and be scheduled to receive:; A medication called ATG as part of your transplant procedure; Steroids (corticosteroids) as part of your treatment at the time of screening; A medication called tacrolimus (or a similar drug) after your transplant, according to usual medical practice
  • Have received certain vaccines before starting the study treatment, specifically:; Pneumococcal (S. pneumoniae); Meningococcal (N. meningitidis types A, C, W, Y, and B); Haemophilus influenzae type B; If you haven't had these vaccines, you may still qualify to be part of the study, provided your doctor plans to administer preventive antibiotics until vaccination can be given per protocol, and with notification to the sponsor

Ki nem vehet részt

  • Have taken part in another medical research study or used an experimental drug, treatment, or device in the past 30 days (or longer, depending on the drug)
  • Have recently used certain medications that affect the immune system, such as rituximab, belimumab, or other approved complement-blocking drugs
  • Have received any other organ transplant (except for one previous kidney transplant), or are scheduled for a transplant involving more than one organ
  • Have or had recently had any of the following infections:; Hepatitis B or Hepatitis C (unless treated and no longer active); HIV (human immunodeficiency virus) at any time
  • Have had cancer in the past 5 years, unless it was:; A small, treated skin cancer (like basal or squamous cell), or; A very small kidney cancer that was found early and treated
  • Weigh less than 20kg or more than 120kg at screening

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

A vizsgálat 2 csoportja

  • PegceptacoplanMár használt kezelés, összehasonlításként

    Administration as a 20mL IV infusion initially, then as a subcutaneous infusion

    Kezelés: Pegcetacoplan

  • PlaceboPlacebo, összehasonlításként

    Administration as a 20mL IV infusion initially, then as a subcutaneous infusion

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
A regiszteradat frissítve
2026. szeptember 2.